Chlamydia Infections Pipeline, Clinical Trials Assessment, NDA Approvals, Emerging Drugs 2023 (Updated) | Evofem Biosciences, Aeterna Zentaris, LinKinVax, Sanofi, and others

DelveInsight's, "Chlamydia Infections Pipeline Insight, 2023," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chlamydia Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Chlamydia Infections Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Chlamydia Infections NDA approvals (if any), and product development activities comprising the technology, Chlamydia Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

To explore more information on the latest breakthroughs in the Chlamydia Infections pipeline treatment landscape of the report, click here @ Chlamydia Infections Pipeline- https://www.delveinsight.com/report-store/chlamydia-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chlamydia Infections Pipeline Report
• DelveInsight's Chlamydia Infections Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
• The leading Chlamydia Infections Companies working in the market include Evofem Biosciences, Aeterna Zentaris, LinKinVax, Sanofi, and others.
• Promising Chlamydia Infections Pipeline Therapies in the various stages of development include EVO100, Doxycyline Hyclate tablet, Vibramycin (doxycyline hyclate) capsule, Rifalazil 25 milligram, Azithromycin 1 gram, solithromycin, ceftriaxone, azithromycin, PRO 2000/5, and others.
• On March 2023, IVIEW Therapeutics Inc announced a study of phase 2 clinical trials for IVIEW-1201. A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Placebo in the Treatment of Adenoviral Conjunctivitis.
• On May 2022, University of California, San Francisco announced a study of phase 4 clinical trials for Doxycycline Hyclate Delayed-Release 200 mg. The purpose of this study is to understand if taking an antibiotic called doxycycline by mouth as soon as possible after sexual contact, can reduce the risk of sexually transmitted infections (STIs), including gonorrhea, chlamydia and syphilis. The study will also look at the safety of doxycycline PEP and the impact that PEP may have on the bacteria that cause STIs as well as on bacteria that normally live on the body. While doxycycline is approved by the Food and Drug Administration (FDA), taking doxycycline immediately after sexual contact to prevent infection is investigational and is not approved by the FDA for this use. Participants will take part in the study for 1 year.

Chlamydia Infections Overview
Chlamydial infection, caused by Chlamydia species, is the most common bacterial sexually transmitted infection and results in substantial morbidity and economic cost worldwide. Chlamydial infections can cause disease in many organ systems, including the genitourinary tract and ocular structures. Chlamydia is a sexually transmitted infectious disease caused by the bacterium Chlamydia trachomatis.

To explore more information on the latest breakthroughs in the Chlamydial infection Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/chlamydia-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chlamydial infection Emerging Drugs Profile
• EVO100: Evofem Biosciences
• Chlamydia Infection Blockers (CIBs): Quretech Bio

Chlamydial infection Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for Chlamydia Infections. The companies which have their Chlamydia Infections drug candidates in the most advanced stage, i.e. phase III include, Evofem Biosciences.

Request a sample and discover the recent advances in Chlamydial infection Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/chlamydia-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chlamydial infection Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Chlamydial infection Therapeutics Market include-
Evofem Biosciences, Aeterna Zentaris, LinKinVax, Sanofi, and others.

Dive deep into rich insights for drugs for Chlamydial infection Pipeline, click here for Chlamydial infection Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/chlamydia-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chlamydial infection Pipeline Report
• Coverage- Global
• Chlamydial infection Companies- Evofem Biosciences, Aeterna Zentaris, LinKinVax, Sanofi, and others.
• Chlamydial infection Pipeline Therapies- EVO100, Doxycyline Hyclate tablet, Vibramycin (doxycyline hyclate) capsule, Rifalazil 25 milligram, Azithromycin 1 gram, solithromycin, ceftriaxone, azithromycin, PRO 2000/5, and others
• Chlamydial infection Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Chlamydial infection Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/chlamydia-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Chlamydia Infections: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chlamydia Infections - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. EVO100: Evofem Biosciences
9. Drug profiles in the detailed report…..
10. Preclinical and Discovery Stage Products
11. Chlamydia Infection Blockers (CIBs): Quretech Bio
12. Drug profiles in the detailed report…..
13. Inactive Products
14. Chlamydia Infections Key Companies
15. Chlamydia Infections Key Products
16. Chlamydia Infections- Unmet Needs
17. Chlamydia Infections- Market Drivers and Barriers
18. Chlamydia Infections- Future Perspectives and Conclusion
19. Chlamydia Infections Analyst Views
20. Chlamydia Infections Key Companies
21. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.